The Experts below are selected from a list of 189 Experts worldwide ranked by ideXlab platform
Thangam Menon - One of the best experts on this subject based on the ideXlab platform.
-
Anti-Mumps Virus activity by extracts of Mimosa pudica, a unique Indian medicinal plant
Indian Journal of Virology, 2013Co-Authors: Jeevan Malayan, Balaji Selvaraj, Aparna Warrier, Manikannan Mathayan, Sambantham Shanmugam, Thangam MenonAbstract::Mumps is an acute and self-limiting disease characterized by parotitis, however in some cases it leads to aseptic meningitis, deafness, encephalitis and orchitis, which is a serious health concern. MMR vaccination was successful in eradicating the disease however, recent reports question the efficacy of MMR vaccine and countless outbreaks are observed in vaccinated populations throughout the world. Lack of specific treatment methods for Mumps infection and inefficiency of MMR vaccine in vaccinated populations accentuates the need for the development of novel drugs to control Mumps Virus mediated serious infections. It was with this backdrop of information that the anti-Mumps Virus activity of Mimosa pudica was evaluated. Suspected Mumps cases were collected to isolate a standard Mumps Virus by systematic laboratory testing which included IgM antibody assays, Virus isolation, RT-PCR and phylogenetic analysis. The Virus was quantified by TCID_50 assay and anti-Mumps Virus property was evaluated by CPE reduction assay and cytotoxicity of the extract was measured by MTT assay and phytochemical analysis was done by gas chromatography-mass spectroscopy. The RT-PCR and phylogenetic tree analysis of the SH gene sequence of the clinical isolate showed it to be Mumps Virus genotype C. 150 μg/ml concentration of M. pudica completely inhibited Mumps Virus and the drug was found to be non-toxic up to 2 mg/ml. M. pudica was thus found to be a potent inhibitor of MuV.
-
Anti-Mumps Virus activity by extracts of Mimosa pudica, a unique Indian medicinal plant
Indian Journal of Virology, 2013Co-Authors: Jeevan Malayan, Balaji Selvaraj, Aparna Warrier, Manikannan Mathayan, Sambantham Shanmugam, Thangam MenonAbstract::Mumps is an acute and self-limiting disease characterized by parotitis, however in some cases it leads to aseptic meningitis, deafness, encephalitis and orchitis, which is a serious health concern. MMR vaccination was successful in eradicating the disease however, recent reports question the efficacy of MMR vaccine and countless outbreaks are observed in vaccinated populations throughout the world. Lack of specific treatment methods for Mumps infection and inefficiency of MMR vaccine in vaccinated populations accentuates the need for the development of novel drugs to control Mumps Virus mediated serious infections. It was with this backdrop of information that the anti-Mumps Virus activity of Mimosa pudica was evaluated. Suspected Mumps cases were collected to isolate a standard Mumps Virus by systematic laboratory testing which included IgM antibody assays, Virus isolation, RT-PCR and phylogenetic analysis. The Virus was quantified by TCID_50 assay and anti-Mumps Virus property was evaluated by CPE reduction assay and cytotoxicity of the extract was measured by MTT assay and phytochemical analysis was done by gas chromatography-mass spectroscopy. The RT-PCR and phylogenetic tree analysis of the SH gene sequence of the clinical isolate showed it to be Mumps Virus genotype C. 150 μg/ml concentration of M. pudica completely inhibited Mumps Virus and the drug was found to be non-toxic up to 2 mg/ml. M. pudica was thus found to be a potent inhibitor of MuV.
Sigrid Gouma - One of the best experts on this subject based on the ideXlab platform.
-
differences in antigenic sites and other functional regions between genotype a and g Mumps Virus surface proteins
Scientific Reports, 2018Co-Authors: Sigrid Gouma, Jeroen Cremer, Tessa Vermeire, Steven Van Gucht, Lennart Martens, Veronik Hutse, Paul A Rota, Geert Lerouxroels, Marion KoopmansAbstract:The surface proteins of the Mumps Virus, the fusion protein (F) and haemagglutinin-neuraminidase (HN), are key factors in Mumps pathogenesis and are important targets for the immune response during Mumps Virus infection. We compared the predicted amino acid sequences of the F and HN genes from Dutch Mumps Virus samples from the pre-vaccine era (1957–1982) with Mumps Virus genotype G strains (from 2004 onwards). Genotype G is the most frequently detected Mumps genotype in recent outbreaks in vaccinated communities, especially in Western Europe, the USA and Japan. Amino acid differences between the Jeryl Lynn vaccine strains (genotype A) and genotype G strains were predominantly located in known B-cell epitopes and in N-linked glycosylation sites on the HN protein. There were eight variable amino acid positions specific to genotype A or genotype G sequences in five known B-cell epitopes of the HN protein. These differences may account for the reported antigenic differences between Jeryl Lynn and genotype G strains. We also found amino acid differences in and near sites on the HN protein that have been reported to play a role in Mumps Virus pathogenesis. These differences may contribute to the occurrence of genotype G outbreaks in vaccinated communities.
-
Mumps Virus F gene and HN gene sequencing as a molecular tool to study Mumps Virus transmission.
Infection genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2016Co-Authors: Sigrid Gouma, Jeroen Cremer, Saara Parkkali, Irene Veldhuijzen, Rob Van Binnendijk, Marion KoopmansAbstract:Various Mumps outbreaks have occurred in the Netherlands since 2004, particularly among persons who had received 2 doses of measles, Mumps, and rubella (MMR) vaccination. Genomic typing of pathogens can be used to track outbreaks, but the established genotyping of Mumps Virus based on the small hydrophobic (SH) gene sequences did not provide sufficient resolution. Therefore, we expanded the sequencing to include fusion (F) gene and haemagglutinin-neuraminidase (HN) gene sequences in addition to the SH gene sequences from 109 Mumps Virus genotype G strains obtained between 2004 and mid 2015 in the Netherlands. When the molecular information from these 3 genes was combined, we were able to identify separate Mumps Virus clusters and track Mumps Virus transmission. The analyses suggested that multiple Mumps Virus introductions occurred in the Netherlands between 2004 and 2015 resulting in several Mumps outbreaks throughout this period, whereas during some local outbreaks the molecular data pointed towards endemic circulation. Combined analysis of epidemiological data and sequence data collected in 2015 showed good support for the phylogenetic clustering.
-
Mumps specific cross neutralization by mmr vaccine induced antibodies predicts protection against Mumps Virus infection
Vaccine, 2016Co-Authors: Sigrid Gouma, Marion Koopmans, Hinke Ten I Hulscher, Tessa Schurinkvant M Klooster, Hester E De Melker, G J Boland, Patricia Kaaijk, Rob Van BinnendijkAbstract:Abstract Background Similar to other recent Mumps genotype G outbreaks worldwide, most Mumps patients during the recent Mumps genotype G outbreaks in the Netherlands had received 2 doses of measles, Mumps and rubella (MMR) vaccine during childhood. Here, we investigate the capacity of vaccine-induced antibodies to neutralize wild type Mumps Virus strains, including Mumps Virus genotype G. Methods In this study, we tested 105 pre-outbreak serum samples from students who had received 2 MMR vaccine doses and who had no Mumps Virus infection ( n = 76), symptomatic Mumps Virus infection ( n = 10) or asymptomatic Mumps Virus infection ( n = 19) during the Mumps outbreaks. In all samples, Mumps-specific IgG concentrations were measured by multiplex immunoassay and neutralization titers were measured against the Jeryl Lynn vaccine strain and against wild type genotype G and genotype D Mumps Virus strains. Results The correlation between Mumps-specific IgG concentrations and neutralization titers against Jeryl Lynn was poor, which suggests that IgG concentrations do not adequately represent immunological protection against Mumps Virus infection by antibody neutralization. Pre-outbreak neutralization titers in infected persons were significantly lower against genotype G than against the vaccine strain. Furthermore, antibody neutralization of wild type Mumps Virus genotype G and genotype D was significantly reduced in pre-outbreak samples from infected persons as compared with non-infected persons. No statistically significant difference was found for the vaccine strain. The sensitivity/specificity ratio was largest for neutralization of the genotype G strain as compared with the genotype D strain and the vaccine strain. Conclusions The reduced neutralization of wild type Mumps Virus strains in MMR vaccinated persons prior to infection indicates that pre-outbreak Mumps Virus neutralization is partly strain-specific and that neutralization differs between infected and non-infected persons. Therefore, we recommend the use of wild type Mumps Virus neutralization assays as preferred tool for surveillance of protection against Mumps Virus infection.
-
Mumps Virus pathogenesis insights and knowledge gaps
Human Vaccines & Immunotherapeutics, 2016Co-Authors: Sigrid Gouma, Marion Koopmans, Rob Van BinnendijkAbstract:The recent Mumps outbreaks among MMR vaccinated persons have raised questions about the biological mechanisms related to Mumps symptoms and complications in the background of waning immunity. Contrary to other paramyxoViruses, the understanding of Mumps Virus pathogenesis is limited, and further in-depth clinical studies are required to provide answers to important research questions.
Curt M Horvath - One of the best experts on this subject based on the ideXlab platform.
-
A Point Mutation, E95D, in the Mumps Virus V Protein Disengages STAT3 Targeting from STAT1 Targeting
Journal of Virology, 2009Co-Authors: Mamta Puri, W. Paul Duprex, Bertus K. Rima, Ken Lemon, Curt M HorvathAbstract:Mumps Virus, like other paramyxoViruses in the RubulaVirus genus, encodes a V protein that can assemble a ubiquitin ligase complex from cellular components, leading to the destruction of cellular signal transducer and activator of transcription (STAT) proteins. While many V proteins target the interferon-activated STAT1 or STAT2 protein, Mumps Virus V protein is unique in its ability to also target STAT3 for ubiquitin modification and proteasome-mediated degradation. Here we report that a single amino acid substitution in the Mumps Virus V protein, E95D, results in defective STAT3 targeting while maintaining the ability to target STAT1. Results indicate that the E95D mutation disrupts the ability of the V protein to associate with STAT3. A recombinant Mumps Virus carrying the E95D mutation in its P and V proteins replicates normally in cultured cells but fails to induce targeting of STAT3. Infection with the recombinant Virus results in the differential regulation of a number of cellular genes compared to wild-type Mumps Virus and increases cell death in infected cells, producing a large-plaque phenotype.
-
STAT3 ubiquitylation and degradation by Mumps Virus suppress cytokine and oncogene signaling.
Journal of Virology, 2003Co-Authors: Christina M. Ulane, Jean Patrick Parisien, Jason J. Rodriguez, Curt M HorvathAbstract:Mumps Virus is a common infectious agent of humans, causing parotitis, meningitis, encephalitis, and orchitis. Like other paramyxoViruses in the genus RubulaVirus, Mumps Virus catalyzes the proteasomal degradation of cellular STAT1 protein, a means for escaping antiviral responses initiated by alpha/beta and gamma interferons. We demonstrate that Mumps Virus also eliminates cellular STAT3, a protein that mediates transcriptional responses to cytokines, growth factors, nonreceptor tyrosine kinases, and a variety of oncogenic stimuli. STAT1 and STAT3 are independently targeted by a single Mumps Virus protein, called V, that assembles STAT-directed ubiquitylation complexes from cellular components, including STAT1, STAT2, STAT3, DDB1, and Cullin4A. Consequently, Mumps Virus V protein prevents responses to interleukin-6 and v-Src signals and can induce apoptosis in STAT3-dependent multiple myeloma cells and transformed murine fibroblasts. These findings demonstrate a unique cytokine and oncogene evasion property of Mumps Virus that provides a molecular basis for its observed oncolytic properties.
Marion Koopmans - One of the best experts on this subject based on the ideXlab platform.
-
differences in antigenic sites and other functional regions between genotype a and g Mumps Virus surface proteins
Scientific Reports, 2018Co-Authors: Sigrid Gouma, Jeroen Cremer, Tessa Vermeire, Steven Van Gucht, Lennart Martens, Veronik Hutse, Paul A Rota, Geert Lerouxroels, Marion KoopmansAbstract:The surface proteins of the Mumps Virus, the fusion protein (F) and haemagglutinin-neuraminidase (HN), are key factors in Mumps pathogenesis and are important targets for the immune response during Mumps Virus infection. We compared the predicted amino acid sequences of the F and HN genes from Dutch Mumps Virus samples from the pre-vaccine era (1957–1982) with Mumps Virus genotype G strains (from 2004 onwards). Genotype G is the most frequently detected Mumps genotype in recent outbreaks in vaccinated communities, especially in Western Europe, the USA and Japan. Amino acid differences between the Jeryl Lynn vaccine strains (genotype A) and genotype G strains were predominantly located in known B-cell epitopes and in N-linked glycosylation sites on the HN protein. There were eight variable amino acid positions specific to genotype A or genotype G sequences in five known B-cell epitopes of the HN protein. These differences may account for the reported antigenic differences between Jeryl Lynn and genotype G strains. We also found amino acid differences in and near sites on the HN protein that have been reported to play a role in Mumps Virus pathogenesis. These differences may contribute to the occurrence of genotype G outbreaks in vaccinated communities.
-
Mumps Virus F gene and HN gene sequencing as a molecular tool to study Mumps Virus transmission.
Infection genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2016Co-Authors: Sigrid Gouma, Jeroen Cremer, Saara Parkkali, Irene Veldhuijzen, Rob Van Binnendijk, Marion KoopmansAbstract:Various Mumps outbreaks have occurred in the Netherlands since 2004, particularly among persons who had received 2 doses of measles, Mumps, and rubella (MMR) vaccination. Genomic typing of pathogens can be used to track outbreaks, but the established genotyping of Mumps Virus based on the small hydrophobic (SH) gene sequences did not provide sufficient resolution. Therefore, we expanded the sequencing to include fusion (F) gene and haemagglutinin-neuraminidase (HN) gene sequences in addition to the SH gene sequences from 109 Mumps Virus genotype G strains obtained between 2004 and mid 2015 in the Netherlands. When the molecular information from these 3 genes was combined, we were able to identify separate Mumps Virus clusters and track Mumps Virus transmission. The analyses suggested that multiple Mumps Virus introductions occurred in the Netherlands between 2004 and 2015 resulting in several Mumps outbreaks throughout this period, whereas during some local outbreaks the molecular data pointed towards endemic circulation. Combined analysis of epidemiological data and sequence data collected in 2015 showed good support for the phylogenetic clustering.
-
Mumps specific cross neutralization by mmr vaccine induced antibodies predicts protection against Mumps Virus infection
Vaccine, 2016Co-Authors: Sigrid Gouma, Marion Koopmans, Hinke Ten I Hulscher, Tessa Schurinkvant M Klooster, Hester E De Melker, G J Boland, Patricia Kaaijk, Rob Van BinnendijkAbstract:Abstract Background Similar to other recent Mumps genotype G outbreaks worldwide, most Mumps patients during the recent Mumps genotype G outbreaks in the Netherlands had received 2 doses of measles, Mumps and rubella (MMR) vaccine during childhood. Here, we investigate the capacity of vaccine-induced antibodies to neutralize wild type Mumps Virus strains, including Mumps Virus genotype G. Methods In this study, we tested 105 pre-outbreak serum samples from students who had received 2 MMR vaccine doses and who had no Mumps Virus infection ( n = 76), symptomatic Mumps Virus infection ( n = 10) or asymptomatic Mumps Virus infection ( n = 19) during the Mumps outbreaks. In all samples, Mumps-specific IgG concentrations were measured by multiplex immunoassay and neutralization titers were measured against the Jeryl Lynn vaccine strain and against wild type genotype G and genotype D Mumps Virus strains. Results The correlation between Mumps-specific IgG concentrations and neutralization titers against Jeryl Lynn was poor, which suggests that IgG concentrations do not adequately represent immunological protection against Mumps Virus infection by antibody neutralization. Pre-outbreak neutralization titers in infected persons were significantly lower against genotype G than against the vaccine strain. Furthermore, antibody neutralization of wild type Mumps Virus genotype G and genotype D was significantly reduced in pre-outbreak samples from infected persons as compared with non-infected persons. No statistically significant difference was found for the vaccine strain. The sensitivity/specificity ratio was largest for neutralization of the genotype G strain as compared with the genotype D strain and the vaccine strain. Conclusions The reduced neutralization of wild type Mumps Virus strains in MMR vaccinated persons prior to infection indicates that pre-outbreak Mumps Virus neutralization is partly strain-specific and that neutralization differs between infected and non-infected persons. Therefore, we recommend the use of wild type Mumps Virus neutralization assays as preferred tool for surveillance of protection against Mumps Virus infection.
-
Mumps Virus pathogenesis insights and knowledge gaps
Human Vaccines & Immunotherapeutics, 2016Co-Authors: Sigrid Gouma, Marion Koopmans, Rob Van BinnendijkAbstract:The recent Mumps outbreaks among MMR vaccinated persons have raised questions about the biological mechanisms related to Mumps symptoms and complications in the background of waning immunity. Contrary to other paramyxoViruses, the understanding of Mumps Virus pathogenesis is limited, and further in-depth clinical studies are required to provide answers to important research questions.
Jeevan Malayan - One of the best experts on this subject based on the ideXlab platform.
-
Anti-Mumps Virus activity by extracts of Mimosa pudica, a unique Indian medicinal plant
Indian Journal of Virology, 2013Co-Authors: Jeevan Malayan, Balaji Selvaraj, Aparna Warrier, Manikannan Mathayan, Sambantham Shanmugam, Thangam MenonAbstract::Mumps is an acute and self-limiting disease characterized by parotitis, however in some cases it leads to aseptic meningitis, deafness, encephalitis and orchitis, which is a serious health concern. MMR vaccination was successful in eradicating the disease however, recent reports question the efficacy of MMR vaccine and countless outbreaks are observed in vaccinated populations throughout the world. Lack of specific treatment methods for Mumps infection and inefficiency of MMR vaccine in vaccinated populations accentuates the need for the development of novel drugs to control Mumps Virus mediated serious infections. It was with this backdrop of information that the anti-Mumps Virus activity of Mimosa pudica was evaluated. Suspected Mumps cases were collected to isolate a standard Mumps Virus by systematic laboratory testing which included IgM antibody assays, Virus isolation, RT-PCR and phylogenetic analysis. The Virus was quantified by TCID_50 assay and anti-Mumps Virus property was evaluated by CPE reduction assay and cytotoxicity of the extract was measured by MTT assay and phytochemical analysis was done by gas chromatography-mass spectroscopy. The RT-PCR and phylogenetic tree analysis of the SH gene sequence of the clinical isolate showed it to be Mumps Virus genotype C. 150 μg/ml concentration of M. pudica completely inhibited Mumps Virus and the drug was found to be non-toxic up to 2 mg/ml. M. pudica was thus found to be a potent inhibitor of MuV.
-
Anti-Mumps Virus activity by extracts of Mimosa pudica, a unique Indian medicinal plant
Indian Journal of Virology, 2013Co-Authors: Jeevan Malayan, Balaji Selvaraj, Aparna Warrier, Manikannan Mathayan, Sambantham Shanmugam, Thangam MenonAbstract::Mumps is an acute and self-limiting disease characterized by parotitis, however in some cases it leads to aseptic meningitis, deafness, encephalitis and orchitis, which is a serious health concern. MMR vaccination was successful in eradicating the disease however, recent reports question the efficacy of MMR vaccine and countless outbreaks are observed in vaccinated populations throughout the world. Lack of specific treatment methods for Mumps infection and inefficiency of MMR vaccine in vaccinated populations accentuates the need for the development of novel drugs to control Mumps Virus mediated serious infections. It was with this backdrop of information that the anti-Mumps Virus activity of Mimosa pudica was evaluated. Suspected Mumps cases were collected to isolate a standard Mumps Virus by systematic laboratory testing which included IgM antibody assays, Virus isolation, RT-PCR and phylogenetic analysis. The Virus was quantified by TCID_50 assay and anti-Mumps Virus property was evaluated by CPE reduction assay and cytotoxicity of the extract was measured by MTT assay and phytochemical analysis was done by gas chromatography-mass spectroscopy. The RT-PCR and phylogenetic tree analysis of the SH gene sequence of the clinical isolate showed it to be Mumps Virus genotype C. 150 μg/ml concentration of M. pudica completely inhibited Mumps Virus and the drug was found to be non-toxic up to 2 mg/ml. M. pudica was thus found to be a potent inhibitor of MuV.
